CA2621564C - Pyridine derivatives and their use in the treatment of psychotic disorders - Google Patents

Pyridine derivatives and their use in the treatment of psychotic disorders Download PDF

Info

Publication number
CA2621564C
CA2621564C CA2621564A CA2621564A CA2621564C CA 2621564 C CA2621564 C CA 2621564C CA 2621564 A CA2621564 A CA 2621564A CA 2621564 A CA2621564 A CA 2621564A CA 2621564 C CA2621564 C CA 2621564C
Authority
CA
Canada
Prior art keywords
mmol
solution
added
disorder
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2621564A
Other languages
English (en)
French (fr)
Other versions
CA2621564A1 (en
Inventor
Giuseppe Alvaro
Daniele Andreotti
Sandro Belvedere
Romano Di Fabio
Alessandro Falchi
Riccardo Giovannini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kandy Therapeutics Ltd
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2621564(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0518472A external-priority patent/GB0518472D0/en
Priority claimed from GB0611153A external-priority patent/GB0611153D0/en
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of CA2621564A1 publication Critical patent/CA2621564A1/en
Application granted granted Critical
Publication of CA2621564C publication Critical patent/CA2621564C/en
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2621564A 2005-09-09 2006-09-07 Pyridine derivatives and their use in the treatment of psychotic disorders Active CA2621564C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0518472.6 2005-09-09
GB0518472A GB0518472D0 (en) 2005-09-09 2005-09-09 Novel compounds
GB0611153.8 2006-06-06
GB0611153A GB0611153D0 (en) 2006-06-06 2006-06-06 Novel compounds
PCT/EP2006/008845 WO2007028654A1 (en) 2005-09-09 2006-09-07 Pyridine derivatives and their use in the treatment of psychotic disorders

Publications (2)

Publication Number Publication Date
CA2621564A1 CA2621564A1 (en) 2007-03-15
CA2621564C true CA2621564C (en) 2014-06-03

Family

ID=37546936

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2621564A Active CA2621564C (en) 2005-09-09 2006-09-07 Pyridine derivatives and their use in the treatment of psychotic disorders

Country Status (28)

Country Link
US (3) US7683056B2 (enExample)
EP (2) EP1928886B1 (enExample)
JP (1) JP5121716B2 (enExample)
KR (1) KR101292348B1 (enExample)
CN (1) CN101305011B (enExample)
AR (1) AR058805A1 (enExample)
AT (1) ATE505472T1 (enExample)
AU (1) AU2006289281B2 (enExample)
BR (1) BRPI0615787B8 (enExample)
CA (1) CA2621564C (enExample)
CR (1) CR9847A (enExample)
CY (1) CY1111907T1 (enExample)
DE (1) DE602006021323D1 (enExample)
DK (1) DK1928886T3 (enExample)
EA (1) EA013909B1 (enExample)
HR (1) HRP20110457T1 (enExample)
IL (1) IL189578A (enExample)
JO (1) JO2722B1 (enExample)
MA (1) MA29780B1 (enExample)
MY (1) MY145713A (enExample)
NO (1) NO340921B1 (enExample)
NZ (1) NZ565983A (enExample)
PE (1) PE20070614A1 (enExample)
PL (1) PL1928886T3 (enExample)
PT (1) PT1928886E (enExample)
SI (1) SI1928886T1 (enExample)
TW (1) TWI378101B (enExample)
WO (1) WO2007028654A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039123A2 (en) * 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
PT2404919E (pt) 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
EA015952B1 (ru) 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
EP2164840A2 (en) 2007-05-09 2010-03-24 Vertex Pharmaceuticals Incorporated Modulators of cftr
CA2989620C (en) 2007-12-07 2022-05-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
HUE049642T2 (hu) 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
EP2098526B1 (en) * 2008-02-22 2014-01-15 Neurotune AG Nitrogen-containing bicyclic compounds active on chronic pain conditions
CA2716109C (en) 2008-02-28 2016-07-19 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
WO2009119528A1 (ja) * 2008-03-24 2009-10-01 武田薬品工業株式会社 複素環化合物
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
EP2145891A1 (en) 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
UY32826A (es) 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
ES2440938T3 (es) * 2009-08-27 2014-01-31 Nerre Therapeutics Limited Formas anhidrato de un derivado de piridina
WO2011054773A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Novel lactam compounds
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
ES2529233T3 (es) 2010-07-09 2015-02-18 Convergence Pharmaceuticals Limited Compuestos tetrazol como bloqueadores de canales de calcio
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
CN102617503B (zh) * 2011-03-03 2014-05-07 上海常丰生物医药科技有限公司 (s)-3-吗啉基羧酸的合成方法
UY34349A (es) 2011-09-29 2013-04-05 Abb Vie Inc OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO
WO2013049164A1 (en) * 2011-09-29 2013-04-04 Abbvie Inc. SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2013359533A1 (en) 2012-12-12 2015-05-28 Abbvie, Inc. Diazepine derivatives useful as calcium channel blockers in the treatment of pain
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
JP6609253B2 (ja) * 2014-08-06 2019-11-20 キッセイ薬品工業株式会社 シアノチオフェン誘導体
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
WO2016102967A1 (en) 2014-12-23 2016-06-30 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
AU2016264034B2 (en) * 2015-05-18 2020-03-05 KaNDy Therapeutics Limited Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
EP3691634A4 (en) 2017-10-05 2021-03-31 Biogen Inc. PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES
EA202092131A1 (ru) * 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
EP4058433A1 (en) * 2019-11-15 2022-09-21 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814
WO2021261969A1 (ko) * 2020-06-26 2021-12-30 홀로스메딕 주식회사 신규한 화합물의 제조방법
KR102682775B1 (ko) * 2020-06-26 2024-07-08 홀로스메딕 주식회사 신규한 화합물의 제조방법
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
JP2024514533A (ja) * 2021-04-05 2024-04-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 神経伝達に対する鏡像異性体選択的作用
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
TW202604529A (zh) 2024-06-18 2026-02-01 瑞士商拜耳保健消費品股份有限公司 用於製造依林奈坦(elinzanetant)前驅物之改良方法
CN122427188A (zh) * 2025-01-21 2026-07-21 安礼特（上海）医药科技有限公司 依林奈坦及其中间体的制备方法
CN122427189A (zh) * 2025-01-21 2026-07-21 安礼特（上海）医药科技有限公司 依林奈坦中间体及依林奈坦的制备方法
WO2026156530A1 (en) 2025-01-22 2026-07-30 Bayer Consumer Care Ag New chemical process for the production of 4- (4-fluoro-2-methyl-phenyl) -5-nitro-1h-pyridin-2-one, a key intermediate of elinzanetant
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921855A (en) 1987-06-22 1990-05-01 Fujisawa Pharmaceutical Co., Ltd. New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same
US5166203A (en) 1990-08-30 1992-11-24 Kanebo, Ltd. Quinolinecarboxylic acid derivatives, antibacterial agent containing the same
EP1486498A1 (en) 1998-11-23 2004-12-15 Pfizer Products Inc. Process and intermediates for growth hormone secretagogues
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
ES2291891T3 (es) 2003-07-03 2008-03-01 F. Hoffmann-La Roche Ag Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia.

Also Published As

Publication number Publication date
CR9847A (es) 2008-07-29
NZ565983A (en) 2011-04-29
AU2006289281B2 (en) 2012-05-17
BRPI0615787B8 (pt) 2021-05-25
PL1928886T3 (pl) 2011-09-30
NO340921B1 (no) 2017-07-17
AU2006289281A1 (en) 2007-03-15
HRP20110457T1 (hr) 2011-07-31
US8097618B2 (en) 2012-01-17
TW200804401A (en) 2008-01-16
AR058805A1 (es) 2008-02-27
EA200800784A1 (ru) 2008-06-30
PE20070614A1 (es) 2007-08-02
DE602006021323D1 (de) 2011-05-26
JP2009507801A (ja) 2009-02-26
US7683056B2 (en) 2010-03-23
US20080269208A1 (en) 2008-10-30
ATE505472T1 (de) 2011-04-15
CY1111907T1 (el) 2015-11-04
US20100152175A1 (en) 2010-06-17
EP1928886B1 (en) 2011-04-13
PT1928886E (pt) 2011-07-14
WO2007028654A1 (en) 2007-03-15
EP1928886A1 (en) 2008-06-11
CN101305011A (zh) 2008-11-12
CA2621564A1 (en) 2007-03-15
CN101305011B (zh) 2011-03-02
EA013909B1 (ru) 2010-08-30
EP2336136A1 (en) 2011-06-22
US7919491B2 (en) 2011-04-05
MY145713A (en) 2012-03-30
BRPI0615787B1 (pt) 2020-08-11
SI1928886T1 (sl) 2011-08-31
MA29780B1 (fr) 2008-09-01
DK1928886T3 (da) 2011-07-11
KR101292348B1 (ko) 2013-09-09
TWI378101B (en) 2012-12-01
NO20081728L (no) 2008-04-07
IL189578A0 (en) 2008-08-07
US20110190276A1 (en) 2011-08-04
JO2722B1 (en) 2013-09-15
IL189578A (en) 2015-10-29
BRPI0615787A2 (pt) 2009-06-16
JP5121716B2 (ja) 2013-01-16
KR20080046232A (ko) 2008-05-26

Similar Documents

Publication Publication Date Title
AU2006289281B2 (en) Pyridine derivatives and their use in the treatment of psychotic disorders
JP2009507801A5 (enExample)
JP2018528203A (ja) Ｉｒａｋ４モジュレーターとしての二環式縮合ヘテロアリールまたはアリール化合物
WO2014078372A1 (en) Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
CA2893256A1 (en) Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2724219C (en) 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists
EP2797922A1 (en) 2 - (pyridin- 2yl) - 1, 7 -diaza-spiro [4.4]nonane- 6 -one compound as voltage-gated sodium channels modulator
US9309254B2 (en) Pyrimidinyl-diazospiro compounds
WO2013179049A1 (en) Spiro derivatives as voltage - gated sodium channel modulators
WO2011054773A1 (en) Novel lactam compounds
US8633214B2 (en) Spiro (piperidine-4,2′-pyrrolidine)-1-(3,5-trifluoromethylphenyl) methylcarboxamides as NK1 tachikynin receptor antagonists
TW202102494A (zh) 抑制環amp-反應元件-結合蛋白(creb)
HK1232519B (en) Novel compounds

Legal Events

Date Code Title Description
EEER Examination request
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251029

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260420

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713